Evidence map›Paper›PMID 32908747›Full record

ArticleCase reports in oncological medicine2020

Inflammatory Myeloradiculitis Secondary to Pembrolizumab: A Case Report and Literature Review.

M L Vickers, B Seidl, K Bigby, B Chern, L Eriksson, G Hartnett, C Gericke, R Chew

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Drug-related immune-mediated myelopathies.Frontiers in neurology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

M L VickersFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-2831-404X
B SeidlDepartment of Medical Oncology, Redcliffe Hospital, Redcliffe, Queensland, Australia.
K BigbyFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
B ChernFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
L ErikssonHerston Health Sciences Library, University of Queensland, Brisbane, Queensland, Australia.
G HartnettDepartment of Medical Oncology, Redcliffe Hospital, Redcliffe, Queensland, Australia.
C GerickeFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
R ChewFaculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
The University of Queensland · AURedcliffe Hospital · AUQueensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors are the most important new medications in oncology and include inhibitors of programmed cell death protein-1 (PD-1) such as Pembrolizumab, Nivolumab, and Cemiplimab. These anticancer agents prevent tumour immune evasion and have been associated with a range of immune-related adverse events (irAEs) including those involving the nervous system. In this case report and literature review, we present the first case of inflammatory myeloradiculitis secondary to Pembrolizumab. We also summarise the characteristics, treatment, and outcomes of other cases reported in the literature which include a component of myelitis. Finally, we make general recommendations on management.

Identifiers

PMID32908747
PMCPMC7450342
OpenAlexW3068952763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.